Seltorexant
JNJ-42847922
What it isSelective orexin-2 receptor antagonist; investigational for insomnia in depression.
Why this oneBlocking only OX2 may separate sleep promotion from the cataplexy risk of dual antagonism.
What limits itInvestigational; not approved. Somnolence as for the class.
FDA-approved for
- insomnia / depression (investigational)
Off-label
- insomnia in major depression (phase 3)
NO BOXED WARNINGS
Principal riskInvestigational; not approved
Classes and tags
Clinical profile
Mechanism of action: Seltorexant ballicule
